# Effect of Dotinurad in Hyperuricemia With Hypertension

Study · id `cardio:ct-nct06834230` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06834230](<https://clinicaltrials.gov/study/NCT06834230>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06834230

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

## Technical summary

Registry record NCT06834230. Randomized; no masking; primary purpose treatment. Start 2025-03-28 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT06834230, source copy `cardio:ctgov-nct06834230-2025-12-15`, retrieved 2026-10-26)
- Started: 2025-03-28 (actual) (ClinicalTrials.gov record NCT06834230, source copy `cardio:ctgov-nct06834230-2025-12-15`, retrieved 2026-10-26)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT06834230, source copy `cardio:ctgov-nct06834230-2025-12-15`, retrieved 2026-10-26)
- Completion: 2030-03-31 (anticipated) (ClinicalTrials.gov record NCT06834230, source copy `cardio:ctgov-nct06834230-2025-12-15`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT06834230, source copy `cardio:ctgov-nct06834230-2025-12-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06834230-2025-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Dotinurad in Hyperuricemia With Hypertension
- Acronym: DIANA-NEXT
- Condition: Hyperuricemia or Gout
- Condition: Hypertension
- Intervention (Drug): Dotinurad
- Intervention (Drug): Febuxostat
- Lead sponsor: Saga University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Saga University (`cardio:org-saga-university`)

## Provenance

Content hash: f17e78cbcd9815a5ddbf643815b57b697f2af2f510d93f2154323397e234a507
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
